Tailored, psychological intervention for anxiety and/or depression in people with chronic obstructive pulmonary disease (COPD), TANDEM (Tailored intervention for ANxiety and DEpression Management in COPD): statistical analysis plan for a randomised controlled trial. by Chan, CL et al.
UPDATE Open Access
Tailored, psychological intervention for
anxiety and/or depression in people with
chronic obstructive pulmonary disease
(COPD), TANDEM (Tailored intervention for
ANxiety and DEpression Management in
COPD): statistical analysis plan for a
randomised controlled trial
Claire L. Chan1* , Melanie Smuk2, Ratna Sohanpal1, Hilary Pinnock3, Stephanie J. C. Taylor1 and On behalf of the
TANDEM Investigators
Abstract
Background: The aim of the TANDEM trial is to evaluate whether a tailored, psychological cognitive behavioural
approach intervention, which links into, and optimises the effects of routine pulmonary rehabilitation (PR), leads to
a reduction in mild/moderate anxiety and/or depression in people with moderate, severe or very severe chronic
obstructive pulmonary disease.
Methods and design: TANDEM is a multi-centre, two-arm, parallel group, pragmatic, individually randomised
controlled, superiority trial including an internal pilot. Participants are randomised to receive either the intervention
(a tailored psychological intervention plus usual care including referral to PR) or the control (usual care including
referral to PR). The designed randomisation ratio is 1.25:1 in favour of the intervention. The multiple-primary
outcomes are participant depression and anxiety at 6 months, measured using the Hospital Anxiety and Depression
Scale (HADS) depression and anxiety subscales.
Results: This article describes the statistical analysis plan (SAP) for the TANDEM trial. In particular, we describe the
general analysis principles, how we will handle missing data, the primary and secondary outcomes and how these
will be analysed, sensitivity analyses for the multiple-primary outcomes, and any other analyses and data
summaries. The SAP was developed and published prior to completion of follow-up of the last participant.
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Background
TANDEM (Tailored intervention for ANxiety and DEpres-
sion Management in chronic obstructive pulmonary disease
(COPD)) is an ongoing multi-centre (twelve NHS trusts),
two-arm, parallel group, pragmatic, individually randomised
controlled, superiority trial including an internal pilot (n=
45). The aim of the pilot was to inform the feasibility of deliv-
ering the intervention, the trial processes, and progression to
the main trial. No assessment of efficacy was made. The pilot
was completed in 2018, and data from this will be incorpo-
rated as an internal pilot as no significant changes were made
to the intervention or study procedures. The protocol for the
TANDEM trial has been published previously [1] and gives
details on the trial rationale, intervention and control groups,
recruitment and study procedures including eligibility cri-
teria, and the sample size calculation.
In brief, people living with COPD are at an increased
risk of depression and anxiety. Pulmonary rehabilitation
(PR) can help but patients commonly fail to attend or
complete PR. The TANDEM trial aims to evaluate
whether a tailored, psychological cognitive behavioural
approach (CBA) intervention, which precedes and opti-
mises the benefits of currently offered PR, leads to a re-
duction in mild/moderate anxiety and/or depression in
people with moderate, severe or very severe COPD.
The planned sample size was 430 participants to achieve
an expected 90% power with an estimated 20% drop out rate.
Participants are randomised with a designed allocation ratio
of 1.25:1 (intervention: control), using minimisation within
each of the twelve NHS Trusts. Participants are allocated
with probability > 1/2 to the treatment group which mini-
mises the overall imbalance between arms at baseline for
anxiety, depression, breathlessness, and smoking status based
on patients already in the trial in each NHS Trust.
The intervention consists of a tailored psychological inter-
vention based on CBA plus usual care including referral to
PR, and the control is usual care (including referral to PR).
‘TANDEM Facilitators’ deliver the intervention on a one to
one basis weekly for 6 to 8 weeks, depending upon the sever-
ity of the anxiety/depression and the participant’s progress.
This is followed by telephone support, if the participant de-
cides to attend PR, prior to the start of PR, during PR, and
2 weeks after completion of PR. The CBA intervention pre-
cedes PR and targets individuals’ cognitions and behaviours
associated with anxiety and depression. The study has a par-
tially clustered design in that participants are clustered by
facilitator in the intervention arm only. In the control group,
usual care follows arrangements for provision of the standard
multidisciplinary PR programme provided in that local area.
In addition, all participants also receive a publicly available
British Lung Foundation (BLF) DVD: “Living with COPD”/
“Stay Well Stay Active” and a publicly available BLF COPD
information and exercise and pulmonary rehabilitation book-
lets. Where applicable, and with participants’ permission,
participants’main carers are invited to join a sub-study to de-
termine the effect of the intervention on carers.
The objectives of the trial are to:
1. Examine the clinical effectiveness of the CBA
intervention on clinical outcomes compared to
usual care.
2. Examine the process outcomes.
3. Examine the effect of the CBA intervention on
carers (where appropriate).
4. Determine the cost-effectiveness of the CBA inter-
vention from an NHS and personal social services
perspective.
5. Conduct a process evaluation to inform the
implementation of the CBA intervention if the trial
is positive, or assist interpretation of findings if it is
negative.
This paper reports on the statistical analysis plan (SAP)
for the trial. The remit of the SAP covers the quantitative
aspect of objectives 1, 2, and 3. Health Economic out-
comes and process outcomes are addressed elsewhere.
A detailed SAP was prepared by the Pragmatic Clinical
Trials Unit (PCTU) trial statistician (CC), and version 1.0
was signed off by the senior statistician (MS) on 10 Febru-
ary 2020 and co-chief investigators (ST and HP) on 10
and 11 February 2020. The SAP is based on protocol ver-
sion 8.0 (29 May 2019). There have been no revisions to
the SAP following version 1.0. All inputting members
were blind to participants’ treatment group allocations.
Reporting follows the Guidelines for the Content of
Statistical Analysis Plans in Clinical Trials [2] (see Add-
itional file 1 populated checklist).
Outcomes
Multiple-primary outcomes
The multiple-primary outcomes are participant depres-
sion and anxiety at 6 months, measured using the
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Hospital Anxiety and Depression Scale (HADS) anx-
iety and depression subscale scores at 6 months
post-randomisation [3]. There are 14 items on the
HADS questionnaire, with each item scored from 0
to 3. The HADS questionnaire has 7 items related to
anxiety (HADS-A) and 7 related to depression
(HADS-D). Scores are totalled across the anxiety
subscale to give a score for anxiety and are totalled
across the depression subscale to give a score for de-
pression. Participants can score between 0 and 21 on
each subscale, with higher scores indicating worse
symptoms of anxiety or depression.
Secondary outcomes
The secondary outcomes measured in study participants
include:
 Depression, measured using HADS-D, at 12 months
 Anxiety, measured using HADS-A, at 12 months
 Depression, measured using Beck Depression
Inventory II (BDI-II), at 6 and 12 months [4]
 Anxiety, measured using Beck Anxiety Inventory
(BAI), at 6 and 12 months [5]
 Smoking status at 6 and 12 months
 Respiratory Health-related quality of life, measured
using St George’s Respiratory Questionnaire
(SGRQ), at 6 and 12 months [6]
 Cognitive and emotional illness perceptions,
measured using the Brief Illness Perception
Questionnaire (B-IPQ), at 6 and 12 months [7]
 Social engagement, measured using the University of
Melbourne Health Education Impact Questionnaire
social engagement scale (heiQ), at 6 and 12months [8]
 Social functioning, measured using an adapted
version of the United Kingdom Time Use Survey, at
6 and 12 months [9]
Secondary outcomes recorded from participants’ main
carers include:
 Carer burden interview, measured using the Zarit
Caregiver Burden Inventory (ZBI), at 6 and 12
months [10]
 Carer mental well-being, measured using the War-
wick Edinburgh Mental Well-Being Scale
(WEMWBS), at 6 and 12 months [11]
Reliability indicators for instruments can be found
within the references given for each instrument. See
Table 1 for information on timing of data collection and
Additional file 2 for information on how outcomes are
derived. Health Economic outcomes (Participant Quality
of life (EQ-5D-5L), Client Service Receipt Inventory, and
Health Care Resource Use), and process outcomes, are
addressed elsewhere.
Analysis methods
General analysis principles
Analyses will follow the intention-to-treat principle. This
requires that all participants be included in the analysis
according to the treatment group to which they were
randomised, regardless of any departures from rando-
mised treatment [13]. Where it is not possible to follow
up participants, we will handle missing data by including
all those with a recorded outcome [14].
Analyses will be presented as:
 The number of participants included in the analysis,
by treatment group
 A summary measure of the outcome, by treatment
group (e.g. mean (standard deviation) for continuous
outcomes)
 A treatment effect (e.g. difference in means for
continuous outcomes) with a 95% confidence
interval
 A two-sided p value
For all analyses, a significance level of 5% will be used,
except when the Hochberg procedure is applied to ac-
count for there being two primary outcomes. We will
use a Hochberg procedure to analyse the two primary
outcomes [15]. Briefly, the Hochberg procedure states
that if either outcome has a p value < 0.025 then that
outcome is statistically significant; additionally, both out-
comes are significant if the p values are both < 0.05. We
assume that the positive dependence assumption of the
Hochberg correction holds. p values will be computed
using the Satterthwaite approximation method [16].
All analyses will account for the partially clustered de-
sign of the study, where participants are clustered by fa-
cilitator in the intervention arm only. Each participant in
the intervention arm will be defined as belonging to a
cluster, defined by which facilitator they belonged to. It
is possible that the facilitator could change for a partici-
pant, for example if a facilitator withdraws and a new fa-
cilitator is assigned to a participant. In such scenarios,
for analysis purposes, we will consider that the partici-
pant is clustered within the facilitator for which they
have had the majority of their sessions. If they had equal
amounts of sessions under multiple facilitators, we will
take the first of such facilitators. The clustering effect by
facilitator in the intervention arm will be modelled using
a partially nested mixed-effects model, which confines
the random effect for cluster to the intervention arm
only. This is achieved by fitting a random slope for treat-
ment group while suppressing the constant from the
random part. This essentially amounts to a random
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intercept for each cluster in the intervention arm and
one intercept for the unclustered control arm [17, 18].
In order to run the model in Stata, it is necessary to im-
pose clustering in the control arm. We therefore will
treat each participant in the control arm as a single clus-
ter to facilitate modelling [18].
All analyses will also account for the correlation be-
tween outcomes at 6 and 12 months using a random ef-
fect for participant. This approach will provide unbiased
estimates even if some participants only provide data at
one of the two time points, under the missing at random
assumption implied by the model. We fit a heteroscedas-
tic model, allowing for different residual level errors in
the two treatment arms since we expect participants in
the intervention arm to vary in a different way to those
in the control arm [17]. The heteroscedastic partially
nested mixed-effects model is recommended in this set-
ting [18], and by implementing the method, we could
possibly yield insight about the treatment [19]. The
model will be estimated using restricted maximum likeli-
hood (REML). Treatment arm, time point (month 6 or
12), and the interaction between treatment arm and time
point will be included in the model as fixed factors.
All analyses will adjust for the outcome measured at
baseline whenever possible. Moreover, analyses will re-
flect the design of the study, and so the stratification and
minimisation variables will be adjusted for [20]. These
covariates will not be interacted with time point. Con-
tinuous covariates will be fitted for the HADS-A and
HADS-D screening scores. Although categories were
used for HADS-A and HADS-D during the minimisa-
tion, we avoid unnecessary categorisation of the covari-
ates for the analysis as this should increase power [21].
Continuous covariates will be assumed to have a linear
relationship with the outcome. Binary covariates will be
fitted for the baseline degree of breathlessness (categor-
ies, 0–2 and 3–4) and baseline smoking status (categor-
ies, smoker and non-smoker (ex-smoker/never
smoked)). We will also adjust for NHS Trust as a fixed
categorical variable instead of a complex (four-level)
mixed effect model due to concerns about model fitting
within the sample size. Furthermore, when there are a
Table 1 Study data collection
Type of data Time of data collectiona Source and method of data
collection
Outcome measure and type
Patient participants
Demographics Baseline Patient participants; supervised
self-complete questionnaire
Clinical:
Breathlessness
Baseline Patient participants; supervised
self-complete questionnaire
mMRC Breathlessness scale;
categorical
Clinical: Smoking
status
Baseline
6 months
12months
Patient participants; supervised
self-complete questionnaire
Smoking status; categorical
Health status
measures
Screening
6months
12months
Patient participants; supervised
self-complete questionnaire
HADS-A and HADS-D; continuous
Baseline
6 months
12months
Patient participants; supervised
self-complete questionnaire
BDI II, BAI, B-IPQ, SGRQ, heiQ, Time
Use Survey (adapted); continuous
PR attendance and
completion data
Once following completion of intervention
delivery
PR service teams Attendance and completion data
CBA attendance
and completion
data
Attendance or failure to deliver recorded at each
session during CBA intervention period
Study team/CBA facilitators Attendance and completion data
Carer participants
Demographics Baseline Carer; self-complete
questionnaire
Wellbeing measures Baseline
6 months
12months
Carer; self-complete
questionnaires
ZBI, WEMWBS; continuous
aNote that for participant 6- and 12-month assessment, every effort is made to collect data at the scheduled time period, but in some cases, follow-up period may
need to be extended ± 4 weeks for logistical/practical reasons
Abbreviations: HADS Hospital Anxiety and Depression Scale (D depression sub-scale, A anxiety subscale) [3], mMRC modified MRC breathlessness scale [12], BAI
Beck Anxiety Inventory [5], BDI II Beck Depression Inventory II [4], SGRQ St George’s Respiratory Questionnaire [6], heiQ University of Melbourne Health Education
Impact Questionnaire social engagement scale [8], B-IPQ The brief illness perception questionnaire [7], ZBI Zarit Caregiver Burden Inventory [10], WEMWBS Warwick
Edinburgh Mental Well-Being Scale [11]
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large number of participants per Trust (25 or more,
which we expect here), random and fixed effects perform
equally well in terms of coverage, power, and efficiency
[22, 23].
All outcomes are continuous except for the binary
outcome smoking status at 6 and 12months (current
smoker vs non-smoker). Since some participants will
already be non-smokers at baseline, for this outcome, we
will present a simple comparison of proportions between
baseline, 6 months, and 12months. Other analyses in-
volving binary outcomes, such as CBA intervention at-
tendance and completion rates, and PR attendance and
completion rates, are discussed later.
Analyses will be carried out using Stata version 14 or
newer. R version 3.6.1 or newer may be used if neces-
sary. The software and version number used will be ref-
erenced with any analysis write up.
See Additional file 3 for table shells and a CONSORT
flow diagram shell.
Missing data
We do not expect missing data for any of the baseline
covariates for the primary analysis. It is possible that
there will be a small amount of missing data for the sec-
ondary outcomes measured at baseline. In this case,
missing data for baseline covariates to be included in the
analysis model will be accounted for using mean imput-
ation [24].
For outcomes that are measured at multiple time
points during follow-up, we have based our analysis
strategy on that proposed by White et al. [14]. To deal
with incomplete data (i.e. when participants have miss-
ing data at one of the follow-up time points), we will:
1. Attempt to follow up all randomised participants
even if they withdraw from the allocated treatment
(but remain in the study).
2. Perform a main analysis of all observed data that
are valid under a plausible assumption about the
missing data.
3. Perform sensitivity analyses to explore the effect of
departures from the assumptions made in the main
analysis.
4. Account for all randomised participants, at least in
the sensitivity analyses.
For the main analyses (point 2), we will include all par-
ticipants with at least one post-randomisation assess-
ment (i.e. if the relevant outcome is recorded for at least
one follow-up time point) in the analysis. Participants
with missing outcome data at both 6 and 12months will
be excluded for this analysis. The mixed-effects model
adjusted for baseline covariates assumes that the data
are missing at random (MAR) [25]. Modelling of the
observed data in this way is a principled method to deal
with missingness, as information is ‘borrowed’ from
other clusters. For outcomes that consist of several items
combined to create a score, we expect most participants
will either complete all or none of the items as observed
in the trial data monitoring. We will thus consider the
summary outcome score as missing if any item is miss-
ing. Only participants who completed all of the ques-
tions which form the score at either 6 or 12 months will
be included in the analysis.
We will perform sensitivity analyses for the primary
outcomes to assess the robustness of our primary ana-
lysis to the missing data assumptions (point 3) and ac-
count for all randomised participants including those
lost to follow up, withdrawn, or found to be ineligible
after randomisation (point 4). We will also compare the
distribution of baseline characteristics of people included
in the primary analysis model and those missing the pri-
mary outcome at both 6 and 12months. Moreover, we
will present the characteristics of people who have miss-
ing follow-up data because they died.
Analysis of multiple-primary outcomes
We will analyse the multiple-primary outcomes separ-
ately. This is equivalent to fitting a joint model in the
case of no missing data. A joint model would be more
efficient in the case where one outcome is missing but
the other outcome is not. However, a joint model is
more computationally complex and it is unlikely that
participants would have completed the HADS-A ques-
tions but not the HADS-D, and vice versa.
A heteroscedastic partially nested mixed-effects model
will be fitted for HADS-A and HADS-D, as follows:
Outcome ¼ β0 þ β1treatþ β2timeþ β3treattime
þ β4trust2þ…þ β14trust12þ β15hadsa
þ β16hadsdþ β17breathþ β18smoke
þ u2treatþ u1 þ ε
where:
treat = Treatment allocation = 0 if control; 1 if
intervention
time = Measurement occasion = 0 if 6 months; 1 if 12
months
trust = NHS Trust = 1 if trust 1; 2 if trust 2; …; 12 if
trust12 (assuming 12 trusts)
hadsa = Baseline HADS-A = (continuous)
hadsd = Baseline HADS-D = (continuous)
breath = Baseline breathlessness = 0 if “0–2”; 1 if “3–4”
smoke = Baseline smoking status = 0 if non-smoker; 1
if smoker
u2 = Facilitator random effect
u1 = Participant random effect
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ε = Residual error
u2|covariates ~ N (0, σ
2
u2)
u1|covariates, u2 ~N (0, σ
2
u1)
ε|(treat = 0) ~N (0, σ2ε0)
ε|(treat = 1) ~N (0, σ2ε1)
Sensitivity analyses for multiple-primary outcomes
Missing data
For the primary analysis, we do not expect missing data
for any of the baseline covariates because they are all
randomisation variables. However, there may be some
missing outcome data which we assume is missing at
random (MAR). MAR is assumed as the most probable
mechanism as the protocol restricts the likelihood of
missing data occurring from a missing not at random
mechanism. Only participants who complete all of the
questions that form the score at either 6 or 12 months
are included in the primary analysis; participants with
missing outcome data at both 6 and 12 months are ex-
cluded. This mixed-effects model adjusted for baseline
covariates assumes the data are MAR.
We will perform the following sensitivity analyses for
the multiple-primary outcomes to assess the robustness
of our primary analysis to different assumptions regard-
ing the missing data:
 A complete case analysis which assumes data
missing at 6 months is missing completely at
random (MCAR)
 An analysis which assumes that data missing at 6
months is missing not at random (MNAR)
For the complete case analysis, we will fit the primary
analysis model but only include participants with fully
recorded data at 6 months. Participants who did not
complete all components of the HADS-A or HADS-D
questions respectively at 6 months will be excluded from
the corresponding analysis.
For the second analysis, we will assess the primary
outcomes under a range of MNAR scenarios. This will
be done following the simple approach proposed by
White et al. [26]. We use the formula Δ =ΔCC + Y1P1 −
Y2P2, where Δ is the treatment effect under the MNAR
scenario, ΔCC is the treatment effect from the complete
case analysis on 6-month data above, Y1 and Y2 are the
assumed 6-month mean responses for participants with
missing data in treatment groups 1 and 2 respectively,
P1 and P2 are the proportion of participants who were
excluded from the 6-month analysis in groups 1 and 2
respectively, and groups 1 and 2 represent the interven-
tion and control groups respectively. The standard error
for Δ is assumed to be approximately equal to the stand-
ard error for ΔCC. Y2 will be varied for both outcomes
between − 10, − 5, − 1.5, 0, 1.5, 5, and 10. Negative
values indicate the participant got less anxious/depressed
at 6 months, positive values indicate they got more so,
and a value of 0 indicates there was no change from
baseline. For each value of Y2, Y1 will be set to Y2 − 5,
Y2, and Y2 + 5. For example, for Y2 = 10 and the HADS-
A outcome, this would indicate an assumption that partic-
ipants in treatment arm 2 (the control arm) who were lost
to follow-up at 6months had gained 10 points on the
HADS-A subscale on average at 6months. Y1 would vary
between 5, 10, and 15, indicating the assumption that par-
ticipants in treatment arm 1 (the intervention arm) who
were lost to follow-up had gained 5 points on the HADS-
A subscale on average at 6months (5 points less than
those in the control arm), 10 points (the same amount as
those in the control arm), or 15 points (5 points more
than those in the control arm). It is possible that the value
of Δ that we obtain may be implausible if it goes outside
the score range of 0–21. In such cases, we will truncate Δ
by the scale boundary. We will note any “tipping point”—
the value the treatment effect in the non-responders
would need to be to change conclusions.
Inclusion criteria
We will perform a sensitivity analysis to assess the im-
pact of including participants in the analysis who have
less room for improvement during follow-up. The inclu-
sion criteria state that participants must have a score of
8 or more on either the HADS anxiety or depression
subscale (but not necessarily both), so some participants
may have a score of < 8 on one of these subscales and
therefore have less room for improvement during
follow-up. We will assess the impact of including such
participants, by repeating the primary analyses for
HADS-A and HADS-D but excluding participants who
have a score of < 8 on the HADS-A and HADS-D sub-
scales respectively. The anxiety and depression subscales
of HADS are strongly associated, [27] meaning that it is
unlikely that many participants have scores a lot lower
than 8 on either subscale.
Time to pulmonary rehabilitation
We will assess the impact of any difference in time from
baseline to attending PR in the intervention and control
groups. We will summarise the time to PR in the two
groups, presenting the mean (standard deviation) and
the median (interquartile range). Furthermore, we will
include time to PR as a covariate in the primary analysis
model and assess the impact.
Internal pilot
We will perform a sensitivity analysis excluding the in-
ternal pilot participants from the primary analysis, to as-
sess the potential impact of a ‘learning effect’ in the
pilot. For example, it is possible that the delay between
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completion of training and the start of intervention de-
livery in the internal pilot may have resulted in the treat-
ment looking less effective in the pilot than later
participants.
Allocation ratio
We are aware that there has been an issue in the ran-
domisation system for a small proportion of participants,
which resulted in a differing allocation ratio for very
brief periods during the trial. We will therefore do a sen-
sitivity analysis stratifying by allocation period. We will
fit the primary analysis model but separately for the par-
ticipants in each of the allocation periods. The results
will then be combined as in a two-stage individual par-
ticipant data meta-analysis [28]. We will also look at the
measured characteristics in each of these groups of par-
ticipants to see if there is evidence that they are different
in each time period, although TANDEM is a fairly rap-
idly recruiting trial and we do not expect this to be the
case. We will also report the balance of minimisation
factors in each NHS Trust.
Analysis of secondary outcomes
HADS-D at 12 months
This outcome is included in the same model as the
HADS-D primary outcome.
HADS-A at 12 months
This outcome is included in the same model as the
HADS-A primary outcome.
BDI-II at 6 and 12 months
These outcomes will be analysed using the same model
as the primary outcomes at 6 and 12months, with base-
line BDI-II as an additional covariate in the model.
BAI at 6 and 12 months
These outcomes will be analysed using the same model
as the primary outcomes at 6 and 12months, with base-
line BAI as an additional covariate in the model.
Smoking status at 6 and 12 months
Smoking status (current smoker vs non-smoker) will be
presented as a simple comparison of proportions be-
tween baseline, 6 months, and 12 months.
SGRQ at 6 and 12 months
Separate models will be fitted for the three component
scores (symptoms, activity, impact) and the total score.
These outcomes will be analysed using the same model
as the primary outcomes at 6 and 12months, with the
relevant component score or total score for SGRQ at
baseline as an additional covariate in the model.
B-IPQ at 6 and 12 months
There are 8 items, with each item scored from 0 to 10.
Each item of the Brief IPQ assesses one dimension of ill-
ness perceptions. Separate models will be fitted for the 8
scores. These outcomes will be analysed using the same
model as the primary outcomes at 6 and 12months,
with the relevant component score for B-IPQ at baseline
as an additional covariate in the model.
heiQ at 6 and 12 months
These outcomes will be analysed using the same model
as the primary outcomes at 6 and 12months, with base-
line heiQ as an additional covariate in the model.
Social functioning (adapted Time Use Survey) at 6 and 12
months
We will analyse the time (minutes) spent doing activities
over the last 4 days. This outcome will be analysed using
the same model as the primary outcomes at 6 and 12
months, with baseline time (minutes) spent doing activ-
ities over the last 4 days as an additional covariate in the
model. Time spent doing activities over the last 4 days
will be assumed to have a linear relationship with the
outcome.
ZBI at 6 and 12 months
These outcomes will be analysed using the same model
as the primary outcomes at 6 and 12months, with base-
line ZBI as an additional covariate in the model.
WEMWBS at 6 and 12 months
These outcomes will be analysed using the same model
as the primary outcomes at 6 and 12months, with base-
line WEMWBS as an additional covariate in the model.
Other analyses and data summaries
Baseline characteristics and questionnaires will be sum-
marised for each treatment group by the mean and
standard deviation or median and interquartile range for
continuous variables, and the number and percentage
for categorical variables.
We will report on CBA intervention attendance and
completion rates and PR attendance and completion
rates. For our analysis, a participant in the intervention
arm is considered to have completed CBA (typically 6–8
sessions) if they complete 2 or more sessions (as per
protocol, completion of two sessions considered mini-
mum effective dose of the intervention). A participant in
either arm of the study is considered to have completed
PR if they complete 75% or more of their scheduled PR
sessions. See Additional file 2 for information on how
the rates are derived.
Finally, we will also report on completeness of data on
questionnaires, and adverse and serious adverse events.
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We do not foresee the need for an interim analysis.
Trial status
At the time of first submission, the TANDEM trial was
ongoing with recruitment having just finished on 19
March 2020 and with follow-up ongoing. Data collection
is anticipated to be completed approximately 12 months
following this date, and all outcomes will be analysed
collectively after this.
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the PCTU and contains, amongst other things, the data
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